Anna E. Vilgelm

3.3k citations

48 papers · 1.9k indexed · h-index 23

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
Immunology top 5%
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Immune Cell Function and Interaction

Papers in ⓘ

Oncology 33
- Cancer-related Molecular Pathways 12
- Cancer Immunotherapy and Biomarkers 11
- CAR-T cell therapy research 5
- Cancer Cells and Metastasis 4
Immunology 17
- Immunotherapy and Immune Responses 11
- Immune cells in cancer 5

Co-authors: Ann Richmond (25 shared papers)Alexander Zaika (8 shared papers)Amrendra Kumar (6 shared papers)Douglas B. Johnson (6 shared papers)Wael El‐Rifai (4 shared papers)Sheau‐Chiann Chen (13 shared papers)Jinming Yang (8 shared papers)Mark C. Kelley (9 shared papers)
Journals: Clinical Cancer Research (4 papers)Cancer Research (4 papers)Cell Reports (3 papers)Oncogene (3 papers)Frontiers in Immunology (2 papers)
Partner nations: United States Russia Taiwan

In The Last Decade

Anna E. Vilgelm

44 papers receiving 1.8k citations

Peers

Countries citing papers authored by Anna E. Vilgelm

Since Specialization

Citations

This map shows the geographic impact of Anna E. Vilgelm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna E. Vilgelm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna E. Vilgelm more than expected).

Fields of papers citing papers by Anna E. Vilgelm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna E. Vilgelm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna E. Vilgelm. The network helps show where Anna E. Vilgelm may publish in the future.

Co-authors

The 25 scholars most cited alongside Anna E. Vilgelm, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anna E. Vilgelm Line = papers co-authored together Anna E. Vilgelm links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy Frontiers in Immunology ·Anna E. Vilgelm, Ann Richmond	2019	266
2	Regulation of p53 Tumor Suppressor by Helicobacter pylori in Gastric Epithelial Cells Gastroenterology ·Jinxiong Wei, Toni A. Nagy, Anna E. Vilgelm, Elena Zaika, Seth R. Ogden, Judith Romero–Gallo, M. Blanca Piazuelo, Pelayo Correa, M. Kay Washington, Wael El‐Rifai, Richard M. Peek, Alexander Zaika	2010	155
3	Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer Frontiers in Immunology ·Amrendra Kumar, Reese Watkins, Anna E. Vilgelm	2021	97
4	PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses Clinical Cancer Research ·Jiqing Sai, Philip Owens, Sergey V. Novitskiy, Oriana E. Hawkins, Anna E. Vilgelm, Jinming Yang, Tammy Sobolik, Nicole Lavender, Andrew C. Johnson, Colt M. McClain, Gregory D. Ayers, Mark C. Kelley, Melinda E. Sanders, Ingrid A. Mayer, Harold L. Moses, Mark Boothby, Ann Richmond	2016	89
5	MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21 Science Translational Medicine ·Anna E. Vilgelm, Nabil Saleh, Rebecca L. Shattuck-Brandt, Kelsie Riemenschneider, Lauren Slesur, Sheau‐Chiann Chen, Christopher Andrew Johnson, Jinming Yang, Ashlyn Blevins, Chi Yan, Douglas B. Johnson, Rami N. Al‐Rohil, Ensar Halilovic, Rondi M. Kauffmann, Mark C. Kelley, Gregory D. Ayers, Ann Richmond	2019	88
6	Combinatorial approach to cancer immunotherapy: strength in numbers Journal of Leukocyte Biology ·Anna E. Vilgelm, Douglas B. Johnson, Ann Richmond	2016	88
7	Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells Cancer Research ·Anna E. Vilgelm, Jeff S. Pawlikowski, Yan Liu, Oriana E. Hawkins, Tyler A. Davis, Jessica Smith, Kevin P. Weller, Linda W. Horton, Colt M. McClain, Gregory D. Ayers, David C. Turner, David C. Essaka, Clinton F. Stewart, Jeffrey A. Sosman, Mark C. Kelley, Jeffrey Ecsedy, Jeffrey N. Johnston, Ann Richmond	2014	82
8	Akt-Mediated Phosphorylation and Activation of Estrogen Receptor α Is Required for Endometrial Neoplastic Transformation in Pten+/− Mice Cancer Research ·Anna E. Vilgelm, Zenglin Lian, Hong Wang, Stephen L. Beauparlant, Andres J. Klein–Szanto, Lora H. Ellenson, Antonio Di Cristofano	2006	79
9	Targeting aurora kinases limits tumour growth through DNA damage‐mediated senescence and blockade of NF‐κB impairs this drug‐induced senescence EMBO Molecular Medicine ·Yan Liu, Oriana E. Hawkins, Yingjun Su, Anna E. Vilgelm, Tammy Sobolik, Yee Mon Thu, Sara Kantrow, Ryan Splittgerber, Sarah P. Short, Katayoun I. Amiri, Jeffery A. Ecsedy, Jeffery A. Sosman, Mark C. Kelley, Ann Richmond	2012	78
10	Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment JNCI Journal of the National Cancer Institute ·Anna E. Vilgelm, Christopher Andrew Johnson, Nripesh Prasad, Jinming Yang, Sheau‐Chiann Chen, Gregory D. Ayers, Jeff S. Pawlikowski, Dayanidhi Raman, Jeffrey A. Sosman, Mark C. Kelley, Jeffrey Ecsedy, Yu Shyr, Shawn Levy, Ann Richmond	2015	70
11	Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors Cell Reports ·Roman V. Uzhachenko, Vijaya Bharti, Zhufeng Ouyang, Ashlyn Blevins, Stacey Mont, Nabil Saleh, Hunter Lawrence, Chengli Shen, Sheau‐Chiann Chen, Gregory D. Ayers, David G. DeNardo, Carlos L. Arteaga, Ann Richmond, Anna E. Vilgelm	2021	61
12	Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms Cancer Immunology Research ·Jinming Yang, Amrendra Kumar, Anna E. Vilgelm, Sheau‐Chiann Chen, Gregory D. Ayers, Sergey V. Novitskiy, Sebastian Joyce, Ann Richmond	2018	57
13	Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity Cancer Immunology Research ·Jinming Yang, Chi Yan, Anna E. Vilgelm, Sheau‐Chiann Chen, Gregory D. Ayers, Christopher Andrew Johnson, Ann Richmond	2020	56
14	Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies ACS Nano ·Yu‐Chuan Ou, Xiaona Wen, Christopher Andrew Johnson, Daniel Shae, Oscar D. Ayala, Joseph A. Webb, Eugene C. Lin, Rossane Delapp, Kelli L. Boyd, Ann Richmond, Anita Mahadevan‐Jansen, Marjan Rafat, John T. Wilson, Justin M. Balko, Mohammed N. Tantawy, Anna E. Vilgelm, Rizia Bardhan	2019	54
15	Interaction of Helicobacter pylori With Gastric Epithelial Cells Is Mediated by the p53 Protein Family Gastroenterology ·Jinxiong Wei, D. O’Brien, Anna E. Vilgelm, M. Blanca Piazuelo, Pelayo Correa, Mary K. Washington, Wael El‐Rifai, Richard M. Peek, Alexander Zaika	2008	52
16	Preparation of (−)-Nutlin-3 Using Enantioselective Organocatalysis at Decagram Scale The Journal of Organic Chemistry ·Tyler A. Davis, Anna E. Vilgelm, Ann Richmond, Jeffrey N. Johnston	2013	52
17	RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors Clinical Cancer Research ·Yingjun Su, Anna E. Vilgelm, Mark C. Kelley, Oriana E. Hawkins, Yan Liu, Kelli L. Boyd, Sara Kantrow, Ryan Splittgerber, Sarah P. Short, Tammy Sobolik, Snjezana Zaja‐Milatovic, Kimberly B. Dahlman, Katayoun I. Amiri, Aixiang Jiang, Lu Wang, Yu Shyr, Darrin D. Stuart, Shawn Levy, Jeffrey A. Sosman, Ann Richmond	2012	47
18	Therapeutic prospects for p73 and p63: Rising from the shadow of p53 Drug Resistance Updates ·Anna E. Vilgelm, Wael El‐Rifai, Alexander Zaika	2008	44
19	ΔNp73α regulates MDR1 expression by inhibiting p53 function Oncogene ·Anna E. Vilgelm, Jinxiong Wei, M. Blanca Piazuelo, M. Kay Washington, Vladimir Prassolov, Wael El‐Rifai, Alexander Zaika	2007	33
20	Interactions of the p53 Protein Family in Cellular Stress Response in Gastrointestinal Tumors Molecular Cancer Therapeutics ·Anna E. Vilgelm, Mary K. Washington, Jinxiong Wei, Heidi Chen, Vladimir Prassolov, Alexander Zaika	2010	32

About Anna E. Vilgelm

Anna E. Vilgelm is a scholar working on Oncology, Immunology, Biotechnology, Cell Biology and Molecular Biology, having authored 48 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (12 papers), Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (11 papers), Cancer Research and Treatments (6 papers), Immune cells in cancer (5 papers), CAR-T cell therapy research (5 papers), Cancer Cells and Metastasis (4 papers) and Microtubule and mitosis dynamics (4 papers). The work is most often cited by research in Oncology (1.0k citations), Immunology (630 citations), Biotechnology (113 citations), Cancer Research (196 citations) and Molecular Biology (773 citations). Anna E. Vilgelm has collaborated with scholars based in United States, Russia and Taiwan. Frequent co-authors include Ann Richmond, Alexander Zaika, Amrendra Kumar, Douglas B. Johnson, Wael El‐Rifai, Sheau‐Chiann Chen, Jinming Yang, Mark C. Kelley, Gregory D. Ayers and Jinxiong Wei. Their work appears in journals such as Clinical Cancer Research, Cancer Research, Cell Reports, Oncogene and Frontiers in Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact